Actinium Pharmaceuticals (ATNM) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning. The brokerage currently has $0.75 target price on the biotechnology company’s stock.
According to Zacks, “Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company’s principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. “
A number of other equities research analysts have also recently commented on the company. Maxim Group set a $3.00 target price on Actinium Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, November 14th. Roth Capital reissued a buy rating and issued a $6.00 target price on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. HC Wainwright reaffirmed a buy rating and set a $6.00 price objective on shares of Actinium Pharmaceuticals in a research report on Monday, October 23rd. Finally, B. Riley initiated coverage on Actinium Pharmaceuticals in a research report on Wednesday, December 6th. They set a buy rating and a $2.75 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus price target of $3.75.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.